Researchers at Yale University have discovered a genetic marker that can help predict ovarian cancer risk. The KRAS-variant was found in 25% of all ovarian cancer patients and 61% of those with a family history of breast and ovarian cancer, suggesting it may be a new marker for high-risk families.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
Two phase-2 trials demonstrate the efficacy of olaparib in treating advanced ovarian and breast cancer in patients with BRCA1 or BRCA2 mutations. The higher dose of olaparib showed better treatment response rates compared to the lower dose, with ORR of 33% and 41% respectively.
Scientists have discovered that ovarian transplants from young mice can restore fertility and increase lifespan in aging female mice. The procedure, which has been performed with limited success in women so far, may also have a rejuvenating effect on their behavior. Researchers believe that similar procedures could be used to preserve ...
Researchers at Arizona State University and Fred Hutchinson Cancer Research Center develop a new method to identify biomarkers for ovarian cancer using antibodies. They found 19 distinct scFvs that selectively bound to proteins exclusively found in ovarian cancerous blood serum, providing potential for significant improvements in patie...
A phase I clinical trial of the combination of decitabine and carboplatin has shown promising results in treating late-stage ovarian cancer, with four patients experiencing no disease progression after six months. The treatment regimen has been found to be well-tolerated, with mild adverse reactions.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
Researchers found that CA-125 change over time can detect invasive, high-grade ovarian cancers at curable stages in post-menopausal women. The study identified a promising first step towards screening, but acknowledges the need for further research and a large-scale randomized trial to confirm the findings.
Researchers found that flaxseed-enriched diets decreased late-stage ovarian tumor severity and increased survival rates in hens. The study also showed improved weight control and reduced metastatic spread in hens fed the flaxseed diet, suggesting potential benefits for human ovarian cancer treatment.
Researchers found that curcumin nanoparticles, delivered via nanoparticles, increased the sensitivity of resistant ovarian cancer cells to chemotherapy and radiation. The treatment enables lower doses of cisplatin and radiation, improving therapeutic outcomes without increasing toxicity.
Fox Chase researchers have discovered that early ovarian cancers arise in inclusion cysts of the ovary. The team found gene expression patterns and extra chromosomes in cells from these cysts compared to normal surface epithelium cells.
Researchers have identified a new breast and ovarian cancer susceptibility gene, RAD51C, in a German study. The gene is associated with a high risk of breast and ovarian cancer, particularly in familial cases.
Researchers have found that patients with hereditary ovarian cancer are more likely to experience secondary tumours in their liver and spleen, despite better overall prognosis. A new approach suggests testing these patients for BRCA1 and BRCA2 genes to ensure tailored treatment.
The Anne Rita Monahan Foundation has raised $50,000 for ovarian cancer research at the Translational Genomics Research Institute (TGen). Funds from the 2nd annual Tea for TEAL event will support the development of a reliable screening test and precision therapy for ovarian cancer.
Researchers at Fox Chase Cancer Center have isolated an engineered antibody, GS45, that targets the Müllerian Inhibiting Substance Type II Receptor on ovarian cancer cells. This unique target is scarce in normal tissue, reducing the risk of side effects associated with traditional targeted therapies.
Researchers found that stress-activated protein protects fugitive ovarian cancer cells from programmed death, allowing them to escape the primary tumor and metastasize. The study suggests that restoring cancer cells' vulnerability to anoikis could suppress tumor growth and metastasis.
Chronic stress accelerates tumor growth in ovarian cancer patients by protecting cells from anoikis, a process that allows tumor cells to survive and grow. Stress hormones norepinephrine and epinephrine activate the protein FAK, leading to accelerated mortality.
Researchers find that stress hormones can protect ovarian cancer cells from anoikis, promoting tumor growth. Higher levels of activated FAK are linked to accelerated mortality in ovarian cancer patients.
Researchers from the University of Gothenburg found that women with a known Western Swedish mutation in the BRCA1 gene have an increased risk of developing ovarian cancer. The study suggests that women without this mutation do not face an elevated risk, and provides clarity for targeted screenings.
Researchers found that GP referrals for gynaecological investigation were delayed for older women with suspected ovarian cancer. Women over 70 years old had a 20-week wait for referral, while those aged 75-79 years had a peak wait of 24 weeks. The discrepancy may be due to differences in data recording and GPs' motivation.
A new study published in the Journal of the American Dietetic Association found a strong relationship between healthy eating and prolonged ovarian cancer survival. Higher consumption of fruits, vegetables, and healthier grains was associated with improved survival rates.
Businessman-philanthropist Foster Friess will match donations up to $50,000 to support TGen's ovarian cancer research. The event has already raised nearly $38,000, with over 500 participants expected.
A woman gave birth to two healthy girls, Aviaja and Lucca, in 2007 and 2008, respectively, after receiving fertility treatment following an ovarian transplant. The breakthrough case report supports the use of cryopreservation of ovarian tissue as a valid method for fertility preservation.
POSITIVE RESULTS is a comprehensive guidebook for those at high risk of breast and ovarian cancer, providing insights into genetics, diagnosis, and treatment options. The book offers a supportive approach to navigating complex decisions, covering genetic testing, screening, mastectomy, and more.
Researchers at Georgia Tech have developed a potential new treatment against ovarian cancer using magnetic nanoparticles to attach to and remove cancer cells from the body. The technique has shown promising results in both mouse and human cancer samples.
Researchers found that ovarian cancer symptoms are not reliable for detecting the disease at an early stage. In fact, only 1 out of 100 women with symptoms will be diagnosed with ovarian cancer. This study highlights the need for better molecular markers and imaging modalities to improve screening for ovarian cancer.
Researchers at Yale University have discovered that stopping the expression of two genes Lin28 and Oct4 can reduce ovarian cancer cell growth and survival. This could lead to more effective treatments for this deadly form of cancer, which has a high recurrence rate and resistance to treatment.
Researchers discovered a noninvasive contrast-enhanced ultrasound imaging technique that can aid in the detection of early-stage ovarian cancer when combined with proteomic blood analyses. This method has shown high accuracy and the potential to save lives by detecting disease at an early stage.
Researchers found that biomarker levels began to rise 3 years before clinical diagnosis, but became substantially elevated only a year prior. While not accurate enough for early intervention, these markers are associated with modest increases in ovarian cancer risk.
Research links BRCA1 gene mutations to lower ovarian response rates in women undergoing fertility preservation treatments for breast cancer. Women carrying the mutated gene are more likely to experience infertility due to decreased egg production.
A genetic signature associated with poor patient outcomes could lead to improved therapies for ovarian cancer. The study found that MAGP2, a previously unknown cancer gene, was overexpressed in tumors of patients who died more quickly.
A new class of compounds containing Ruthenium and Osmium has been found to be highly effective in killing ovarian and colon cancer cells, even those resistant to Cisplatin. The discovery is a significant step forward in the field of medicinal chemistry.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
The Fox Chase-Penn Ovarian SPORE program will focus on three central concepts in ovarian cancer: epigenetics, predictive biomarkers, and targeted therapeutics. The grant will fund five main research projects and three core facilities to support multidisciplinary research efforts.
Researchers at the University of Gothenburg have developed a new treatment that uses a radioactive substance to seek and destroy tumour cells in ovarian cancer patients. The treatment, which has shown no unwanted side-effects in an initial study, aims to provide a more effective alternative to current treatments.
A new genetic marker associated with ovarian cancer risk was discovered by a research group led by scientists from the University of Hawaii at Manoa. The marker is present among 32% of women and contributes an estimated 0.7% to ovarian cancer risk, particularly for serous carcinoma subtype.
A new study published in the American Cancer Society's journal finds that young women with early-stage ovarian cancer can preserve future fertility by conserving at least one ovary or the uterus. Researchers analyzed data from over 1,800 patients and found those who conserved an ovary had similar survival rates for up to five years.
A new gene therapy technique using nanoparticles has shown promise in suppressing ovarian tumor growth in mice, offering a potential treatment for late-stage ovarian cancer. The nanoparticles deliver a killer gene that kills cells by disrupting protein production, avoiding toxic side effects common with traditional chemotherapy.
Researchers developed nanoparticles that selectively delivered diphtheria toxin genes to ovarian cancer cells, slowing tumor growth and increasing lifespan by nearly four weeks. This therapy shows promise as a targeted treatment for advanced ovarian cancer.
A novel immunoconjugate targeting EphA2 protein shows substantial antitumor activity in ovarian cancer cell lines and mice. The agent inhibits tumor growth by 85% compared to control, with significant effects on proliferation and apoptosis.
Researchers developed a novel therapeutic delivery system that targets EphA2 protein in ovarian cancer cells, delivering chemotherapy with high specificity and reducing tumor growth by up to 98%. The therapy shows promising results in preclinical models and is expected to enter phase I clinical trials soon.
Researchers developed models to understand the growth and progression of serous ovarian cancer, identifying key properties for a biomarker-based screening test. The study aimed to guide rational design of an early detection strategy, potentially leading to improved outcomes for women diagnosed with this aggressive type of ovarian cancer.
Current diagnostic tests for ovarian cancer are ineffective for early detection, but a new study suggests that with improved testing, tumors can be detected up to 4.3 years before diagnosis and treatment is possible. The window of opportunity for successful treatment is surprisingly long, making reliable early detection crucial.
Early-stage ovarian tumors can remain undetectable for years due to their small size, posing a significant challenge in early detection. The study suggests that detecting these microscopic tumors within a four-year window could enable surgeons to remove them before they spread.
Researchers at Dartmouth Medical School have developed a Trojan horse nanoparticles to target ovarian cancer, reprogramming protective cells into killers. The approach triggers an inflammatory immune response, directly killing tumor cells and potentially complementing current therapies.
Women taking hormone therapy have a 38% increased risk of ovarian cancer, with risks increasing by 44% for epithelial tumors. The absolute risk is approximately 1 extra ovarian cancer for every 8,300 women taking hormone therapy annually.
Researchers found that ultrasound outperforms symptom analysis in detecting ovarian cancer, with TVS performing better for malignancies. Racial disparities in colorectal cancer survival dissipate after adjusting for demographic and clinical factors. Thyroid cancer incidence increases across all tumor sizes, suggesting screening is not ...
A new study found that African-American patients with breast, ovarian, and prostate cancer tend to die earlier than patients of other races, even when controlling for medical treatment and socioeconomic factors. The analysis of over 20,000 patient records suggests a potential role for genetic factors in the survival gap.
A recent study found that women with diminished ovarian reserve are at increased risk of trisomic pregnancy, regardless of age. The study analyzed data from 19,840 women undergoing fertility treatment in the Netherlands and found a history of ovarian surgery, low egg retrieval, or menopausal status to significantly increase trisomy risk.
Researchers found that ultra-fast freezing of ovarian tissue can achieve the same success rate as fresh tissue in transplants, with a viability rate of 91.9% compared to 88.9%. The cortical grafting technique allows for simpler procedure with equally successful results, enabling women to have children later in life.
A new ovarian transplantation technique has successfully restored fertility in two patients who had lost their ovaries due to cancer treatment. The two-step procedure involves grafting small pieces of frozen ovarian tissue before the main transplant, allowing for faster recovery of ovarian function and improved response to stimulation.
A new study published in Journal of General Internal Medicine found that few women with family histories of hereditary breast or ovarian cancer are discussing genetic testing with their physicians. Most high-risk women are unaware of the available test or have not discussed it with their clinician.
Researchers found genetic variations in miRNA processing genes and binding sites associated with increased ovarian cancer risk and shorter survival times. Variations also indicated likelihood of response to platinum-based chemotherapy, potentially using a single blood sample for prognosis and therapy prediction.
A pre-clinical study found that adding dasatinib to standard chemotherapy increases the effectiveness of treatment in ovarian cancers with high SRC expression. This synergistic effect was absent in low SRC expressing cancers, suggesting targeted therapies like dasatinib may improve response rates.
A new study found that ultrasound and blood test screening for ovarian cancer only catches the disease in its late stages, resulting in unnecessary surgery. The positive predictive value of these tests is remarkably low, leading to many false positives.
A study at Duke University Medical Center suggests that ovarian cancers detected early on may be slower-growing and less likely to spread than more aggressive forms. This finding challenges the idea of screening for ovarian cancer as a means of reducing mortality.
The largest randomised trial of ovarian cancer screening has shown that both the CA125 blood test and transvaginal ultrasound screening strategies are capable of detecting early stage ovarian cancers. The study detected almost half of all cancers in stage I/II, with a significant improvement in specificity for multimodal screening.
The Ovarian Cancer Research Fund (OCRF) and the Gynecologic Cancer Foundation (GCF) have jointly funded a new study on ovarian cancer symptoms, aiming to develop a systematic screening process. Dr. Barbara Goff will lead the three-year study, which seeks to create a symptom index for early detection.
Research finds that increased angiogenesis and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. High microvessel density and VEGF overexpression were linked to significantly poorer survival rates, as well as recurrence and metastasis.
Primary ovarian insufficiency is a menopause-like condition affecting girls and young women, characterized by loss of menstrual periods, infertility, and hot flashes. A comprehensive plan provides recommendations for diagnosis and treatment, including hormone replacement therapy and counseling.